Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 280 participants.
Also called NCT07586540
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 280 participants
- Sponsor
- Middle East North Africa Stroke and Interventional Neurotherapies Organization
- Registry
-
NCT07586540
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Egypt, Jordan, Morocco, Pakistan, Qatar, Saudi Arabia, Tunisia, Türkiye
- Registry status
- Recruiting
Technical summary
Registry record NCT07586540. Randomized; triple masking; primary purpose treatment. Start 2026-01-06 (actual); primary completion 2030-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Alirocumab for Stabilisation of Symptomatic Vulnerable Carotid Plaque
- Acronym
- CAROTID-STABIL
- Condition
- Carotid Stenosis
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Atorvastatin
- Lead sponsor
- Middle East North Africa Stroke and Interventional Neurotherapies Organization
Record details
- Record id
cardio:ct-nct07586540- Content hash
cc5314ea7b90162c1c8d032c6cdadde6af2fd061727d5d7a3021e818bf2c5a6e